[go: up one dir, main page]

DE60140972D1 - Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen - Google Patents

Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen

Info

Publication number
DE60140972D1
DE60140972D1 DE60140972T DE60140972T DE60140972D1 DE 60140972 D1 DE60140972 D1 DE 60140972D1 DE 60140972 T DE60140972 T DE 60140972T DE 60140972 T DE60140972 T DE 60140972T DE 60140972 D1 DE60140972 D1 DE 60140972D1
Authority
DE
Germany
Prior art keywords
diagnostic
antibodies against
therapeutic compounds
cryptosporidium parvum
parvum antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140972T
Other languages
English (en)
Inventor
J Neil Simonsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Original Assignee
University of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba filed Critical University of Manitoba
Application granted granted Critical
Publication of DE60140972D1 publication Critical patent/DE60140972D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60140972T 2000-06-15 2001-06-15 Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen Expired - Lifetime DE60140972D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21208300P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
DE60140972D1 true DE60140972D1 (de) 2010-02-11

Family

ID=22789489

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60140972T Expired - Lifetime DE60140972D1 (de) 2000-06-15 2001-06-15 Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen
DE60135655T Expired - Lifetime DE60135655D1 (de) 2000-06-15 2001-06-15 Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60135655T Expired - Lifetime DE60135655D1 (de) 2000-06-15 2001-06-15 Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen

Country Status (8)

Country Link
US (4) US6808900B2 (de)
EP (2) EP1294889B1 (de)
AT (2) ATE407209T1 (de)
AU (1) AU6720601A (de)
CA (1) CA2411949C (de)
DE (2) DE60140972D1 (de)
ES (1) ES2313962T3 (de)
WO (1) WO2001096370A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
DK2371383T3 (en) 2005-12-29 2015-11-30 Boehringer Ingelheim Vetmed Use of a PCV2 immunogenic composition for reduction of clinical symptoms in pigs
EP3868400A1 (de) 2005-12-29 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Multivalente immunogene pcv2-zusammensetzungen und verfahren zur herstellung solcher zusammensetzungen
EP2099927A4 (de) * 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed Verfahren zur reduzierung von mit schweine-circovirus assoziierten krankheitsausbrüchen
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
US8865183B2 (en) * 2006-12-15 2014-10-21 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with PCV2 antigent
EP1941903A1 (de) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxe und Behandlung von PRDC
EP1958644A1 (de) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Vorbeugung und Behandlung von subklinischer PCVD
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CA2710558A1 (en) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 virus like particle with foreign amino acid insertion
US20090317423A1 (en) * 2008-01-23 2009-12-24 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CN103503841B (zh) * 2013-09-29 2016-01-20 捷胜海洋装备股份有限公司 一种浮球牵引机的牵引结构
WO2015051099A1 (en) 2013-10-02 2015-04-09 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 protein variant and virus like particles composed thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024649A1 (en) 1992-05-29 1993-12-09 The Regents Of The University Of California Cryptosporidium polypeptides, nucleic acid, vectors and methods of use
DK0663010T3 (da) * 1992-10-02 2000-11-13 Res Corp Technologies Inc Fremgangsmåde til forøgelse af sekretion af overudtrykte proteiner
US5591434A (en) 1993-05-26 1997-01-07 The United States Of America As Represented By The Secretary Of Agriculture DNA sequence encoding surface protein of cryptosporidium parvum
US6323020B1 (en) * 1996-08-23 2001-11-27 North Carolina State University Neutralization-sensitive epitopes of Cryptosporidium parvum

Also Published As

Publication number Publication date
EP1762620A2 (de) 2007-03-14
US20080299143A1 (en) 2008-12-04
AU6720601A (en) 2001-12-24
ATE453714T1 (de) 2010-01-15
US8241871B2 (en) 2012-08-14
US20050064553A1 (en) 2005-03-24
EP1762620B1 (de) 2009-12-30
EP1762620A3 (de) 2007-04-04
EP1294889A2 (de) 2003-03-26
EP1294889B1 (de) 2008-09-03
WO2001096370A3 (en) 2003-01-03
WO2001096370A9 (en) 2002-09-19
US7850972B2 (en) 2010-12-14
US7288621B2 (en) 2007-10-30
ES2313962T3 (es) 2009-03-16
CA2411949C (en) 2012-05-22
US20120045464A1 (en) 2012-02-23
US6808900B2 (en) 2004-10-26
US20020034516A1 (en) 2002-03-21
CA2411949A1 (en) 2001-12-20
WO2001096370A2 (en) 2001-12-20
ATE407209T1 (de) 2008-09-15
DE60135655D1 (de) 2008-10-16

Similar Documents

Publication Publication Date Title
DE60140972D1 (de) Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
AU9063801A (en) Methods and compositions for diseases associated with amyloidosis
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
DE60027890D1 (de) Streptococcus pneumoniae proteine und impfstoffe
AU6867801A (en) Fusion proteins of mycobacterium tuberculosis
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
WO2005007673A3 (en) Immunogenic peptides
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
DE60042816D1 (de) T-helferzellen-epitope
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe
ATE313560T1 (de) Therapeutische anti-cytomegalovirus verbindungen
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
ATE414154T1 (de) Moraxella (branhamella) catarrhalis antigene
ATE421586T1 (de) Moraxella (branhamella) catarrhalis antigene
NO20042124L (no) Thymosinforsterkning ved genetisk immunisering
WO1999027955A3 (en) Treatment of established chronic infections and cancers

Legal Events

Date Code Title Description
8364 No opposition during term of opposition